These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30726251)

  • 1. A systematic study of microdosing psychedelics.
    Polito V; Stevenson RJ
    PLoS One; 2019; 14(2):e0211023. PubMed ID: 30726251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
    Anderson T; Petranker R; Rosenbaum D; Weissman CR; Dinh-Williams LA; Hui K; Hapke E; Farb NAS
    Psychopharmacology (Berl); 2019 Feb; 236(2):731-740. PubMed ID: 30604183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
    Lea T; Amada N; Jungaberle H; Schecke H; Scherbaum N; Klein M
    Psychopharmacology (Berl); 2020 May; 237(5):1521-1532. PubMed ID: 32043165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelic microdosing benefits and challenges: an empirical codebook.
    Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E
    Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting.
    Prochazkova L; Lippelt DP; Colzato LS; Kuchar M; Sjoerds Z; Hommel B
    Psychopharmacology (Berl); 2018 Dec; 235(12):3401-3413. PubMed ID: 30357434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.
    Rootman JM; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Kuypers KPC; Polito V; Bourzat F; Walsh Z
    Sci Rep; 2021 Nov; 11(1):22479. PubMed ID: 34795334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.
    Ryan RS; Copello A; Fox AP
    BMC Psychiatry; 2023 Mar; 23(1):160. PubMed ID: 36918852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field.
    Polito V; Liknaitzky P
    Neurosci Biobehav Rev; 2022 Aug; 139():104706. PubMed ID: 35609684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
    Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR
    J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Narrative identity, rationality, and microdosing classic psychedelics.
    Webb M; Copes H; Hendricks PS
    Int J Drug Policy; 2019 Aug; 70():33-39. PubMed ID: 31071597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.
    Kuypers KP; Ng L; Erritzoe D; Knudsen GM; Nichols CD; Nichols DE; Pani L; Soula A; Nutt D
    J Psychopharmacol; 2019 Sep; 33(9):1039-1057. PubMed ID: 31303095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing.
    Kaertner LS; Steinborn MB; Kettner H; Spriggs MJ; Roseman L; Buchborn T; Balaet M; Timmermann C; Erritzoe D; Carhart-Harris RL
    Sci Rep; 2021 Jan; 11(1):1941. PubMed ID: 33479342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review.
    Lo DF; Zia H; Rajkumar P; Thakur A; O'Donnell H
    Prim Care Companion CNS Disord; 2024 Jan; 26(1):. PubMed ID: 38228068
    [No Abstract]   [Full Text] [Related]  

  • 17. Motives and Side-Effects of Microdosing With Psychedelics Among Users.
    Hutten NRPW; Mason NL; Dolder PC; Kuypers KPC
    Int J Neuropsychopharmacol; 2019 Jul; 22(7):426-434. PubMed ID: 31152167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychedelic Microdosing: A Subreddit Analysis.
    Lea T; Amada N; Jungaberle H
    J Psychoactive Drugs; 2020; 52(2):101-112. PubMed ID: 31648596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State Cannabis and Psychedelic Legislation and Microdosing Interest in the US.
    Yang KH; Satybaldiyeva N; Allen MR; Ayers JW; Leas EC
    JAMA Health Forum; 2024 Jun; 5(6):e241653. PubMed ID: 38941086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
    Rootman JM; Kiraga M; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Kuypers KPC; Walsh Z
    Sci Rep; 2022 Jun; 12(1):11091. PubMed ID: 35773270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.